The oncogenic property of LMO2 was also confirmed in transgenic mouse models[7] and in X-SCID patients treated with retrovirus-mediated gene therapy, in which T-ALL emerged due to the insertion of retroviral sequence that incurs aberrant expression of LMO2 [8]. Here, LMO2 is linked to acute lymphoblastic leukemia.